Defining the clinical validity of genes reported to cause pulmonary arterial hypertensionCarrie L. Welch, David Langleben, Micheala A. Aldred et al.|Genetics in Medicine|2023Cited by 73
Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial HypertensionGéraldine Vitry, Sébastien Bonnet, Roxane Paulin et al.|American Journal of Respiratory and Critical Care Medicine|2020Cited by 34
ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changesYann Grobs, Sébastien Bonnet, Charlotte Romanet et al.|Science Translational Medicine|2024Cited by 33
Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical StudiesSarah‐Eve Lemay, Sébastien Bonnet, James J. Dowling et al.|Circulation|2025Cited by 26
Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial HypertensionYann Grobs, Sébastien Bonnet, Charifa Awada et al.|International Journal of Molecular Sciences|2021Cited by 16